Latest Headlines

Latest Headlines

Japan's Daiichi Sankyo joins clinical trial data request system

Tokyo-based Daiichi Sankyo said it would join with a mix of foreign multinationals and Japanese companies in sharing clinical trial data with qualified researchers.

Sanofi's Brandicourt mulls pulling the plug on Merck JV: Bloomberg

Back in 1994, Merck and Pasteur Merieux Connaught--now Sanofi Pasteur--teamed up on a joint venture to develop and market vaccines in Europe. Now, as Sanofi chief Olivier Brandicourt reorganizes the French pharma's operations in a cost-cutting bid, the 21-year-old partnership could be on the chopping block.

GlaxoSmithKline up-sizes its bet on Adaptimmune, racing forward with a cancer immunotherapy

GlaxoSmithKline, working with Adaptimmune on therapies that use the body's machinery to fight cancer, is sweetening the deal for its partner, promising more cash to accelerate development of a promising treatment for soft tissue sarcoma.

IBM partners with micro-cap Bionik for machine learning algorithms in robotic exoskeleton

Several companies are working on robotic exoskeletons to enable more mobility for paraplegics, but few have focused on the data that could be generated from them. Now IBM has partnered with microcap robotic exoskeleton player Bionik Laboratories to apply its machine-learning algorithms in an effort to analyze data to improve the outcomes of neurological rehabilitation.

IBM Watson, AHA and Welltok to develop workplace heart health program

The American Heart Association, IBM Watson Health and wearable data player Welltok have teamed up to develop a solution to help America's largest employers advance workplace health. This will be the first application of Watson's supercomputing powers to cardiovascular health.

Bristol-Myers, Pfizer and Eisai bet big biobucks on the Japanese market

Bristol-Myers Squibb, Pfizer and Eisai are targeting Japan's growing pharma market with a pair of deals in the cardiovascular and oncology spaces, signing back-loaded agreements to push new drugs in the country.

Lilly considers taking the plunge on a next-gen GLP-1 drug for diabetes

Canada's Transition Therapeutics is touting positive Phase II data for a once-a-week GLP-1 treatment, triggering a decision point for partner Eli Lilly, which bought into the program in a $247 million deal.

Merck bets up to $515M on an epigenetic project for cancer and blood disease

Merck is buying into a Cancer Research U.K. program that targets an enzyme key to the development of cancer and blood disease, wagering as much as $515 million on the effort.

Boston Scientific, Accenture partner for chronic cardio population health analytics

Boston Scientific will support its largest business segment, cardiovascular, by rolling out a cloud-based digital care solution that's aimed at giving hospitals greater insight into their chronic cardiovascular population and patients. To do so, it's teamed up with software giant Accenture.

In the midst of cuts, Parexel signs new research deal

CRO giant Parexel has inked a new pact with the Optum Life Sciences unit of the nation's largest insurer, UnitedHealth Group, to help lower costs in postapproval studies.